𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Biological activity of two botulinum toxin type A complexes (Dysport®and Botox®) in volunteers

✍ Scribed by K. Wohlfarth; I. Schwandt; F. Wegner; T. Jürgens; G. Gelbrich; A. Wagner; U. Bogdahn; W. Schulte-Mattler

Publisher
Springer
Year
2008
Tongue
English
Weight
298 KB
Volume
255
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

DYSBOT: A single-blind, randomized paral
DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1
✍ Dr. Cristina Sampaio; Joaquim J. Ferreira; Fernanda Simões; Maria J. Rosas; Mari 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 561 KB

## Background: Elston and russell discovered a difference in the biological potency of the english formulation of botulinum toxin type a or btx-a (dysport) and the american formulation (botox). potency of both is expressed in ld50 mouse units, but because of assay differences, these units are not e

Efficacy and safety of botulinum type A
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study
✍ Daniel Truong; Drake D. Duane; Joseph Jankovic; Carlos Singer; Lauren C. Seeberg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

## Abstract Botulinum toxin type A (Dysport) has been shown in European studies to be a safe and effective treatment for cervical dystonia. This multicenter, double‐blind, randomized, controlled trial assessed the safety and efficacy of Dysport in cervical dystonia patients in the United States. Ei

The variability in the clinical effect i
The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in humans
✍ Dr. R. Eleopra; V. Tugnoli; D. de Grandis 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 648 KB

## Abstract When botulinum toxin (BT) is administered for the first time at fixed doses, variable clinical responses can be observed in patients with the same form of dystonic disorder. Many factors may contribute to this phenomenon, including the variability in the rate of absorption of the drug.